Journal article
Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years.
Abstract
438
Background: Until recently there were no standard treatments for HCC patients after S. This study characterizes subsequent treatments (STx) received by HCC patients over the past 10 years and assesses their impact on survival. Methods: HCC patients treated with S between 01/2008 – 06/2017 in British Columbia, Alberta, and two cancer centers in Toronto, Ontario, Canada (Princess Margaret and Sunnybrook Cancer Centre) were …
Authors
Fung AS; Lee-Ying RM; Meyers DE; Sim H-W; Knox JJ; Zaborska VO; Davies JM; Ko Y-J; Batuyong E; Cheung WY
Journal
Journal of Clinical Oncology, Vol. 37, No. 4_suppl, pp. 438–438
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 1, 2019
DOI
10.1200/jco.2019.37.4_suppl.438
ISSN
0732-183X